nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2006 | Review

DNA vaccines for cancer too

verfasst von: Min Yu, Olivera J. Finn

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Excerpt

Vaccines based on DNA encoding the antigens, rather than antigenic proteins or peptides, is a recently developed approach that has the potential to elicit strong and long-lasting immunity while also having several practical advantages over other vaccines [1]. DNA vaccines can be conveniently and cheaply produced and purified. They do not require special handling or storage conditions. Also, unlike viral vectors that can elicit immune responses to the vector proteins as well as to the immunizing DNA, naked DNA vaccines elicit immune responses only to the encoded antigen of interest. This allows their repeated use to boost immune responses without loosing immunogenicity by provoking an immune attack against the vector-encoded proteins [2]. …

Haupt K, Roggendorf M, Mann K (2002) The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) 227:227–237

Liu MA (1998) Vaccine developments. Nat Med 4:515–519PubMed

Lewis JD, Reilly BD, Bright RK (2003) Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 22:81–112PubMed

Sinkovics JG, Horvath JC (2000) Vaccination against human cancers (review). Int J Oncol 16:81–96PubMed

Yannelli JR, Wroblewski JM (2004) On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23:97–113CrossRefPubMed

Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ’self’ tumour antigens. Immunology 93:192–199PubMed

Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29:121–125PubMed

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998–1008PubMed

Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62:217–256PubMedCrossRef

10.

Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN (1998) Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188:1075–1082CrossRefPubMed

11.

Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B (1999) DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 189:169–178PubMed

12.

Doe B, Selby M, Barnett S, Baenziger J, Walker CM (1996) Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A 93:8578–8583CrossRefPubMed

13.

Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478CrossRefPubMed

14.

Corr M, Lee DJ, Carson DA, Tighe H (1996) Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555–1560CrossRefPubMed

15.

Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, Wang S, Liu X, Donnelly JJ, Liu MA (1997) Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3:362–371PubMed

16.

Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC (2003) Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 112:109–117CrossRefPubMed

17.

Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T, Wilson DM, Ayyavoo V, Weiner DB (2000) Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 18:974–979CrossRefPubMed

18.

Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL (2001) Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 19:543–547CrossRefPubMed

19.

Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP (2000) Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60:51–55PubMed

20.

Hauser H, Chen SY (2003) Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31:225–231CrossRefPubMed

21.

Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, Sun YJ, Zhang XM, Sui YF (2004) Heat shock protein 70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo. Cancer Immunol Immunother 53:825–834CrossRefPubMed

22.

Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A (1992) Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1:363–369PubMed

23.

Rock KL, Clark K (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721–3726PubMed

24.

York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369–396CrossRefPubMed

25.

Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918–921PubMed

26.

Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R (2004) CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259–264CrossRefPubMed

27.

Amici A, Venanzi FM, Concetti A (1998) Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 47:183–190CrossRefPubMed

28.

Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T (1999) T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 189:803–810CrossRefPubMed

29.

von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL (1996) CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 70:1072–1079PubMed

30.

Dyer CM, Zhan Y, Brady JL, Carbone FR, Smyth MJ, Lew AM (2004) Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after DNA immunization. Blood 103:3073–3075CrossRefPubMed

31.

Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89PubMed

32.

Heath WR, Carbone FR (2001) Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1:126–134CrossRefPubMed

33.

Davis HL, Millan CL, Watkins SC (1997) Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther 4:181–188CrossRefPubMed

34.

Zhang L, Widera G, Bleecher S, Zaharoff DA, Mossop B, Rabussay D (2003) Accelerated immune response to DNA vaccines. DNA Cell Biol 22:815–822CrossRefPubMed

35.

Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O’Hagan D, Donnelly J, Widera G, Rabussay D, Lewis MG, Barnett S, Ulmer JB (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22:2489–2493CrossRefPubMed

36.

Kaur R, Rauthan M, Vrati S (2004) Immunogenicity in mice of a cationic microparticle-adsorbed plasmid DNA encoding Japanese encephalitis virus envelope protein. Vaccine 22:2776–2782CrossRefPubMed

37.

Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15CrossRefPubMed

38.

Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207CrossRefPubMed

39.

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515–1525CrossRefPubMed

40.

Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Gaudernack G (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399–1400CrossRefPubMed

41.

Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA (1993) A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53:3257–3261PubMed

42.

Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781–1787PubMed

43.

Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570–4577PubMed

44.

Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Tezuka N, Sawai S, Inoue S, Fujino S, Maeda T, Itoh Y, Ogasawara K, Sato H, Ohkubo I, Kudo T (2002) Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther 9:330–337CrossRefPubMed

45.

Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993–11997PubMed

46.

Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY (2004) Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 111:86–95CrossRefPubMed

47.

Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313–1323CrossRefPubMed

48.

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89:293–300CrossRefPubMed

49.

Hodge JW (1996) Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 43:127–134CrossRefPubMed

50.

Zhou H, Luo Y, Mizutani M, Mizutani N, Becker JC, Primus FJ, Xiang R, Reisfeld RA (2004) A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 113:1792–1798CrossRefPubMed

51.

Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV (2005) A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF). Vaccine 23:1273–1283CrossRefPubMed

52.

Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, Shaw DR, LoBuglio AF (2002) Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8:2782–2787PubMed

53.

Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14:709–714CrossRefPubMed

54.

Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMed

55.

Graham RA, Burchell JM, Taylor-Papadimitriou J (1996) The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 42:71–80CrossRefPubMed

56.

Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688–694PubMed

57.

Nawrath M, Pavlovic J, Moelling K (2001) Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J Mol Med 79:133–142CrossRefPubMed

58.

Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ (2000) Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128:273–280CrossRefPubMed

59.

Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN (1999) Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190:1717–1722CrossRefPubMed

60.

O I, Blaszczyk-Thurin M, Shen CT, Ertl HC (2003) A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther 10:678–688CrossRefPubMed

61.

Srinivasan R, Houghton AN, Wolchok JD (2002) Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun 2:8PubMed

62.

Wolchok JD, Srinivasan R, Perales MA, Houghton AN, Bowne WB, Blachere NE (2001) Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. Cancer Immun 1:9PubMed

63.

Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patino JA, Wolchok JD, Scheinberg DA, Houghton AN (2005) CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma. Clin Cancer Res 11:370–379PubMed

64.

Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845–5852PubMed

65.

Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK (1997) DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 159:1885–1892PubMed

66.

King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4:1281–1286CrossRefPubMed

67.

Forconi F, King CA, Sahota SS, Kennaway CK, Russell NH, Stevenson FK (2002) Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Immunology 107:39–45CrossRefPubMed

68.

Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK (2001) Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 19:760–764CrossRefPubMed

69.

Ruffini PA, Neelapu SS, Kwak LW, Biragyn A (2002) Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87:989–1001PubMed

70.

Hakim I, Levy S, Levy R (1996) A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 157:5503–5511PubMed

71.

De Marco F, Hallez S, Brulet JM, Gesche F, Marzano P, Flamini S, Marcante ML, Venuti A (2003) DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res 23:1449–1454PubMed

72.

Rocha-Zavaleta L, Alejandre JE, Garcia-Carranca A (2002) Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 66:86–95CrossRefPubMed

73.

Chu NR, Wu HB, Wu TC, Boux LJ, Mizzen LA, Siegel MI (2000) Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 5:401–540CrossRefPubMed

74.

Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM (2003) Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16:111–121CrossRefPubMed

75.

Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8:1028–1037PubMed

76.

Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369–1375CrossRefPubMed

77.

Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC (2001) Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 8:128–138CrossRefPubMed

78.

Cheng L, Ziegelhoffer PR, Yang NS (1993) In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A 90:4455–4459PubMed

79.

Tanigawa K, Yu H, Sun R, Nickoloff BJ, Chang AE (2000) Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother 48:635–643CrossRefPubMed

80.

Drabick JJ, Glasspool-Malone J, King A, Malone RW (2001) Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3:249–255CrossRefPubMed

81.

Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F (2001) Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 61:859–863PubMed

82.

Hobson P, Barnfield C, Barnes A, Klavinskis LS (2003) Mucosal immunization with DNA vaccines. Methods 31:217–224CrossRefPubMed

83.

Klavinskis LS, Barnfield C, Gao L, Parker S (1999) Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162:254–262PubMed

84.

Perrie Y, Frederik PM, Gregoriadis G (2001) Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 19:3301–3310CrossRefPubMed

85.

Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, Greenberg HB, Herrmann JE (1998) Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72:5757–5761PubMed

86.

Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5:387–391CrossRefPubMed

87.

Freimark BD, Blezinger HP, Florack VJ, Nordstrom JL, Long SD, Deshpande D.S, Nochumson S, Petrak KL (1998) Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 160:4580–4586PubMed

88.

Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M, Plewe M, Liang X, Norman J, Smith A, Cheng SH (1996) A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A 93:11454–11459CrossRefPubMed

89.

Barnfield C, Brew R, Tilling R, Rae A, Wheeler C, Klavinskis LS (2000) The cellular basis of immune induction at mucosal surfaces by DNA vaccination. Dev Biol (Basel) 104:159–164

90.

Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM (1991) Biodegradable microspheres as a vaccine delivery system. Mol Immunol 28:287–294CrossRefPubMed

91.

Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L (2003) Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21:1478–1485CrossRefPubMed

92.

Toka FN, Pack CD, Rouse BT (2004) Molecular adjuvants for mucosal immunity. Immunol Rev 199:100–112CrossRefPubMed

93.

Klinman DM (2003) CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2:305–315CrossRefPubMed

94.

Audibert F (2003) Adjuvants for vaccines a quest. Int Immunopharmacol 3:1187–1193CrossRefPubMed

95.

Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98:9237–9242CrossRefPubMed

96.

Krieg AM (2004) Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6:88–95PubMed

97.

More SH, Breloer M, von Bonin A (2001) Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells. Int Immunol 13:1121–1127CrossRefPubMed

98.

Binder RJ, Han DK, Srivastava PK (2000) CD91: a receptor for heat shock protein gp96. Nat Immunol 1:151–155CrossRefPubMed

99.

Li Z, Menoret A, Srivastava P (2002) Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14:45–51CrossRefPubMed

100.

Amigorena S (1998) Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res Immunol 149:661–662CrossRefPubMed

101.

Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, Reimann J (2002) Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol 168:108–117PubMed

102.

Xiang Z, Ertl HC (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129–135CrossRefPubMed

103.

Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P (1993) Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 91:566–576PubMed

104.

Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252CrossRefPubMed

105.

Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, Wu TC (2001) Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61:1080–1088PubMed

106.

Sin JI, Kim J, Chattergoon M, Ayyavoo V, McCallus D, Ugen KE, Boyer JD, Weiner DB (2000) Engineering of DNA vaccines using molecular adjuvant plasmids. Dev Biol (Basel) 104:187–198

107.

Hurwitz AA, Kwon ED, van Elsas A (2000) Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589–596CrossRefPubMed

108.

Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA (1997) Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 159:4999–5004PubMed

109.

Dhiman N, Bonilla R, O’Kane DJ, Poland GA (2001) Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20:22–30CrossRefPubMed

110.

Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG (2000) Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 110:374–381CrossRefPubMed

111.

Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555–561CrossRefPubMed

112.

Alizadeh AA, Staudt LM (2000) Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol 12:219–225CrossRefPubMed

113.

Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3:56–63CrossRefPubMed

114.

Wang T, Hopkins DA, Fan L, Fanger G.R, Houghton R, Vedvick TS, Repasky E, Reed SG (2001) A p53 homologue and a novel serine proteinase inhibitor are over-expressed in lung squamous cell carcinoma. Lung Cancer 34:363–374CrossRefPubMed

115.

Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, Reed SG (2001) L552S, an alternatively spliced isoform of XAGE-1:is over-expressed in lung adenocarcinoma. Oncogene 20:7699–7709CrossRefPubMed

116.

Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG (2003) L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88:887–894CrossRefPubMed

Titel: DNA vaccines for cancer too
verfasst von: Min Yu
Olivera J. Finn
Publikationsdatum: 01.02.2006
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-005-0008-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

DNA vaccines for cancer too

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Immunotherapy in chronic lymphocytic leukemia

Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin

T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression

Binding parameters of antibodies: pseudo-affinity and other misconceptions

Immune defects in patients with chronic lymphocytic leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie